Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV open-label study of tildrakizumab in moderate-to-severe chronic plaque psoriasis
2019-002804-42Phase 4Active
- Sponsor
- Almirall
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tildrakizumab in psoriasis and plaque psoriasis, sponsored by Almirall. Primary endpoints: Absolute PASI score at Week 24 and Absolute change from baseline in PASI at Week 24. Started Aug 2019; status: active.
02
Drugs
tildrakizumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2019-002804-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002804-42.